Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update – Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or COPD – – Results from Phase 3 study of rademikibart in moderate-to-severe AD presented in late-breaking research session at AAD – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute

#CNTB Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Announces $20.2 Million Private Placement Financing Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a clinical-stage biopharmaceutical company

#CNTB Connect Biopharma Announces $20.2 Million Private Placement Financing

www.stocktitan.net/news/CNTB/connect-biopha...

Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study Connect Biopharma (Nasdaq: CNTB) reported Phase 3 RADIANT-AD results for rademikibart, presented at AAD 2026. In a 52-week trial (n=259), rademikibart achieved durable responses: EASI-75 96.6%, IGA 0/1 87.1%, and EASI-90 85.3%, with safety comparable to placebo and low conjunctivitis rates.The study used 300 mg SC every two weeks with a 16-week induction and 36-week maintenance phase; company to host a March 30, 2026 webcast and call.

#CNTB Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

www.stocktitan.net/news/CNTB/rademikibart-d...

Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD Connect Biopharma (Nasdaq: CNTB) reported positive topline Phase 1 results for IV rademikibart (300 mg 2-minute IV push) in asthma and COPD patients on March 30, 2026. Patients showed rapid FEV1 gains (≥200 mL in many) within 15 minutes, with mean improvements ~200–400 mL maintained through Day 29. The drug was generally well tolerated with no serious or severe AEs. Connect is recruiting Phase 2 Seabreeze STAT studies for acute exacerbations and expects topline Phase 2 data mid-2026, then plans FDA discussions on a Phase 3 program.

#CNTB Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

www.stocktitan.net/news/CNTB/connect-biopha...

INVESTIR💲 ds les biens publics, tels que le port de Cotonou, poumon économique du Bénin via le #GlobalGateway passe par un vrai dialogue social pour un travail décent & une protection sociale pr tous les👷‍♀️👷‍♀️du Port - #FowardFest M. Bachabi de la
#CNTB
@acv-csc-europe.bsky.social @11.be @enabel.be

Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 Connect Biopharma (Nasdaq: CNTB) highlighted new mechanism‑of‑action data for rademikibart and outlined 2026 priorities, emphasizing clinical execution. Mechanistic studies show enhanced IL‑4R binding, greater internalization versus dupilumab, and stronger rescue of β‑agonist responsiveness in human airway models, supporting faster, larger FEV1 improvements observed previously. Ongoing Phase 1b IV study has shown preliminary faster FEV1 increases versus subcutaneous dosing with topline results expected in Q1 2026. Phase 2 Seabreeze STAT asthma and COPD trials are recruiting with topline data expected mid‑2026. Cash, cash equivalents and short‑term investments were $54.8M as of Sept 30, 2025, with runway into 2027 under current plans.

#CNTB Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 – – New Drug Application for rademikibart for the treatment of atopic dermatitis submitted by Simcere, the Company’s exclusive licensee in

#CNTB Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025 Connect Biopharma (NASDAQ:CNTB) presented promising data for rademikibart, their investigational anti-IL-4Rα antibody, at the European Respiratory Society Congress 2025. The Phase 2b trial results showed significant improvements in lung function and asthma control, particularly in patients with elevated type 2 inflammatory markers.Key findings include a 507 mL improvement in prebronchodilator FEV1 at Week 24 in patients with high EOS and FeNO levels, and substantial reductions in asthma exacerbations (63% reduction in high EOS patients and 69% reduction in high FeNO patients). The company expects to report topline data from ongoing Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD in 1H 2026.

#CNTB Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025

www.stocktitan.net/news/CNTB/connect-biopha...

New Asthma Treatment Data: Connect Biopharma's Rademikibart Shows Impact on FEV1 in Type 2 Asthma Trial Connect Biopharma will present two studies on Rademikibart for moderate-to-severe asthma at ERS 2025, focusing on eosinophil impact and FEV1 improvements in Type 2 asthma patients.

#CNTB Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025

www.stocktitan.net/news/CNTB/connect-biopha...

Biotech Connect Biopharma Completes Strategic Shift to Direct Nasdaq Listing for U.S. Growth Connect Biopharma transitions from ADR to direct Nasdaq listing, exchanging ADRs 1:1 for ordinary shares. Company advances Phase 2 Seabreeze STAT studies for rademikibart in asthma/COPD treatment.

#CNTB Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide Connect Biopharma (NASDAQ:CNTB) has partnered with former Cincinnati Bengals running back Ickey Woods and the Jovante Woods Foundation to expand a nationwide asthma education program. The initiative, launched on August 14, 2025, commemorates the death of Woods' 16-year-old son Jovante from an acute asthma attack in 2010.The collaboration includes a video package featuring Jovante's story and will expand educational events across new U.S. markets during the 2025 NFL season. Connect Biopharma is currently conducting Phase 2 Seabreeze STAT studies for acute asthma exacerbations, with topline data expected in H1 2026.According to CDC data, over 1 million people annually visit emergency departments for acute asthma exacerbations, with up to 30% requiring hospitalization. Approximately 50% experience worsening or new exacerbations within four weeks, and over 3,500 people die from asthma yearly in the U.S.

#CNTB Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Posts Q2 Revenue Drop | The Motley Fool

#CNTB #7fd375cb-453a-4da3-a132-35adc77937e5 #data-news

Origin | Interest | Match

Connect Biopharma's Asthma Drug Shows Promise as Company Restructures for US Growth Clinical-stage biotech reports progress on rademikibart trials for asthma/COPD, submits China NDA, and plans Nasdaq listing change. $71.8M cash runway extends to 2027. Learn more.

#CNTB Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq Connect Biopharma (Nasdaq: CNTB), a clinical-stage biopharmaceutical company, has announced plans to terminate its American Depositary Receipt (ADR) program and directly list its ordinary shares on the Nasdaq Global Market. The transition is scheduled for September 2, 2025, with ADRs being exchanged for ordinary shares at a one-for-one ratio.The company will maintain its current trading symbol "CNTB" after the transition. CEO Barry Quart emphasized that this move represents a strategic step toward becoming a U.S.-centric company, aiming to increase institutional visibility and eliminate ADR depositary fees. The company continues to advance its Phase 2 clinical development program for rademikibart in asthma and COPD treatment.

#CNTB Connect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on Nasdaq

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress Connect Biopharma presented clinical data for rademikibart, their investigational anti-IL-4Rα antibody, at EAACI 2025. The Phase 2b trial results showed significant improvements in lung function and asthma control for patients with eosinophilic-driven type 2 asthma. Rademikibart demonstrated rapid improvement in prebronchodilator FEV1 from Week 1, sustained through 24 weeks. The drug achieved notable reductions in annualized asthma exacerbation rates: 63% in patients with elevated baseline eosinophils, 69% in elevated FeNO patients, and 74% in those with both markers elevated. The company expects to report topline data from ongoing Phase 2 acute exacerbation studies in asthma and COPD in the first half of 2026.

#CNTB Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

www.stocktitan.net/news/CNTB/connect-biopha...

New Clinical Data: Connect Biopharma's Asthma Drug Shows Promising Results in Two EAACI Presentations Key findings on Rademikibart's impact on asthma exacerbations and lung function to be revealed at prestigious EAACI 2025 Congress. Get exclusive insights.

#CNTB Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

www.stocktitan.net/news/CNTB/connect-biopha...

New Asthma Drug Shows 24-Hour Lung Function Improvement, Superior Safety vs Dupilumab at ATS 2025 Connect Biopharma's rademikibart demonstrates rapid FEV1 improvement and enhanced IL-4Rα inhibition vs dupilumab in asthma patients. See full trial results.

#CNTB Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update Connect Biopharma (NASDAQ: CNTB) reported Q1 2025 financial results and significant progress in its clinical development programs. The company initiated two Phase 2 Seabreeze STAT studies evaluating rademikibart for acute exacerbations in both asthma and COPD, with topline data expected in 1H 2026. Published data showed promising results, with rademikibart demonstrating rapid improvements in lung function, particularly in eosinophilic-driven asthma patients showing a +420 mL difference from placebo. The company maintains a strong financial position with $84.0 million in cash and investments, providing runway into 2027. Q1 2025 resulted in a net loss of $10.3 million ($0.19 per share), compared to $8.7 million ($0.16 per share) in Q1 2024.

#CNTB Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD Connect Biopharma (NASDAQ: CNTB) has initiated its Phase 2 Seabreeze STAT COPD study to evaluate rademikibart as a treatment for acute exacerbations in COPD patients. The study, approved by the FDA, will assess the drug's safety and efficacy as an adjunct to standard care in patients with COPD and type 2 inflammation.The trial will enroll approximately 160 participants globally with acute COPD exacerbation and eosinophil count ≥300 cells/μL. Participants will receive either a single dose of rademikibart or placebo. The primary endpoint will measure treatment failure rate over 28 days following acute exacerbation. The company expects to report topline data in 1H 2026.This initiative follows promising post-hoc analysis from their Phase 2b Asthma study, showing potential benefits particularly in patients with elevated baseline eosinophil counts. Currently, about 1.3 million patients visit emergency departments annually for COPD flare-ups, with 50% experiencing treatment failure within four weeks.

#CNTB Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma Connect Biopharma (NASDAQ: CNTB) has initiated the Phase 2 Seabreeze STAT Asthma study to evaluate rademikibart as an adjunct treatment for acute asthma exacerbations. The study, approved by the FDA, will assess the drug's safety and efficacy in approximately 160 participants with asthma and type 2 inflammation. Previous Phase 2 trial results published in AJRCCM showed rademikibart's ability to improve lung function within 24 hours of administration, with sustained improvements through 24 weeks. The primary endpoint will measure treatment failure rate over 28 days following an acute exacerbation. The company expects to report topline data in 1H 2026 and plans to initiate a similar Phase 2 study in COPD patients. If successful, rademikibart could become the first biologic indicated for acute asthma exacerbations.

#CNTB Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart Connect Biopharma (NASDAQ: CNTB) has received positive feedback from the FDA regarding its Type C meeting for rademikibart, advancing plans for two parallel Phase 2 trials in Q2 2025. The trials will evaluate the drug's effectiveness in patients with moderate-to-severe asthma or COPD experiencing acute exacerbations.Each trial will enroll approximately 160 patients with eosinophils ≥300 cells/µL, testing a single 600 mg subcutaneous dose of rademikibart over 28 days following an acute exacerbation. Previous Phase 2 studies showed the drug was well-tolerated and improved pulmonary function within 24 hours.The company expects to report trial data in H1 2026 and maintains a cash runway into 2027. Currently, about 45% of patients receiving standard care experience treatment failure within 28 days post-exacerbation, highlighting a significant unmet medical need.

#CNTB Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma Connect Biopharma (NASDAQ: CNTB) has published positive results from its global Phase 2 trial of rademikibart for moderate-to-severe uncontrolled asthma in the American Journal of Respiratory and Critical Care Medicine. The study involved 322 adult patients randomized to receive either 150mg or 300mg of rademikibart or placebo for 24 weeks.Key findings include:Significant improvement in lung function starting week 1 and sustained through 24 weeksIn patients with ≥300 eosinophils/µL, the mean difference from placebo in FEV1 was +420 mL at Week 24Fewer acute exacerbations in treatment groups (24 events in 214 patients) versus placebo (26 events in 108 patients)No serious treatment-related adverse events reportedBased on these results, the FDA has agreed to advance rademikibart into Phase 3 trials for asthma maintenance treatment.

#CNTB Connect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Achieves Major Turnaround: $26M Revenue, Slashes Losses, Plans Key Clinical Trials Strong financials fuel expansion as Connect Biopharma reports first-ever revenue, reduces losses, and advances clinical pipeline. Full analysis of growth strategy inside.

#CNTB Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update

www.stocktitan.net/news/CNTB/connect-biopha...

Connect Biopharma Gets 180-Day Grace Period to Meet Nasdaq $1 Price Rule Connect Biopharma granted 180 days to regain Nasdaq compliance. Shares continue trading while company addresses sub-$1 price issue. See compliance strategy.

#CNTB Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

www.stocktitan.net/news/CNTB/connect-biopha...